Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC).Thierry Andre,Kai-Keen Shiu,Tae Won Kim,Benny Vittrup Jensen,Lars Henrik Jensen,Cornelis J. A. Punt,Denis Michel Smith,Rocio Garcia-Carbonero, Julia Alcaide,Peter Gibbs,Christelle De la Fouchardiere,Fernando Rivera,Elena Elez,Johanna C. Bendell,Dung T. Le,Takayuki Yoshino,Wen Yan Zhong,David R. Fogelman,Patricia Marinello,Luis A. DiazJOURNAL OF CLINICAL ONCOLOGY（2021）引用 57|浏览9暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
